Expand MIRA Menu
MIRA MENU

MIRA Latest Press Releases

-- September 1, 2026 --

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND Globe Newswire 8:00 AM

-- August 6, 2026 --

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 Globe Newswire 8:00 AM

-- July 30, 2026 --

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies Globe Newswire 8:00 AM

-- July 10, 2026 --

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain ACCESS Newswire 8:00 AM

-- July 6, 2026 --

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction ACCESS Newswire 9:00 AM

-- June 25, 2026 --

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC ACCESS Newswire 8:15 AM

-- June 17, 2026 --

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy ACCESS Newswire 8:00 AM

-- June 4, 2026 --

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 ACCESS Newswire 8:00 AM

-- May 27, 2026 --

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN ACCESS Newswire 8:00 AM

-- May 14, 2026 --

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 ACCESS Newswire 8:05 AM

-- May 13, 2026 --

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate ACCESS Newswire 8:00 AM
Market Data Delayed 15 Minutes